Dianthus Therapeutics Future Growth
Future criteria checks 2/6
Dianthus Therapeutics's earnings are forecast to decline at 17.8% per annum while its annual revenue is expected to grow at 62.4% per year. EPS is expected to decline by 12.4% per annum.
Key information
-17.8%
Earnings growth rate
-12.4%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 62.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 11 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4 | -160 | -129 | -125 | 9 |
| 12/31/2025 | 4 | -129 | -113 | -95 | 10 |
| 12/31/2024 | 5 | -85 | -77 | -78 | 10 |
| 9/30/2024 | 5 | -67 | -63 | -63 | N/A |
| 6/30/2024 | 4 | -57 | -51 | -51 | N/A |
| 3/31/2024 | 3 | -50 | -42 | -42 | N/A |
| 12/31/2023 | 3 | -44 | -37 | -37 | N/A |
| 9/30/2023 | 4 | -43 | -34 | -34 | N/A |
| 6/30/2023 | 4 | -36 | -32 | -32 | N/A |
| 3/31/2023 | 6 | -31 | -34 | -34 | N/A |
| 12/31/2022 | 6 | -28 | -29 | -29 | N/A |
| 12/31/2021 | 1 | -13 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 87E is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 87E is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 87E is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 87E's revenue (62.4% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 87E's revenue (62.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 87E's Return on Equity is forecast to be high in 3 years time